|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Bayer |
| Information provided by: | Bayer |
| ClinicalTrials.gov Identifier: | NCT00105443 |
Purpose
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients with liver cancer.
| Condition | Intervention | Phase |
|
Cancer Liver Cancer Hepatocellular Carcinoma (HCC) |
Drug: Nexavar (Sorafenib, BAY43-9006) |
Phase III |
| MedlinePlus related topics: | Cancer Liver Cancer |
| ChemIDplus related topics: | Sorafenib Sorafenib tosylate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 45 Study Locations |
| Bayer |
More Information
| Study ID Numbers: | 100554 |
| First Received: | March 14, 2005 |
| Last Updated: | September 27, 2006 |
| ClinicalTrials.gov Identifier: | NCT00105443 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|